PE20252433A1 - Composiciones y metodos para la degradacion selectiva de proteinas disenadas por ingenieria - Google Patents
Composiciones y metodos para la degradacion selectiva de proteinas disenadas por ingenieriaInfo
- Publication number
- PE20252433A1 PE20252433A1 PE2024000202A PE2024000202A PE20252433A1 PE 20252433 A1 PE20252433 A1 PE 20252433A1 PE 2024000202 A PE2024000202 A PE 2024000202A PE 2024000202 A PE2024000202 A PE 2024000202A PE 20252433 A1 PE20252433 A1 PE 20252433A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- methods
- engineered proteins
- selective degradation
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230225P | 2021-08-06 | 2021-08-06 | |
| PCT/US2022/074589 WO2023015283A1 (en) | 2021-08-06 | 2022-08-05 | Compositions and methods for selective degradation of engineered proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20252433A1 true PE20252433A1 (es) | 2025-10-20 |
Family
ID=83692652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000202A PE20252433A1 (es) | 2021-08-06 | 2022-08-05 | Composiciones y metodos para la degradacion selectiva de proteinas disenadas por ingenieria |
Country Status (15)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022405474B2 (en) * | 2021-12-08 | 2026-08-13 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| GB202304214D0 (en) * | 2023-03-23 | 2023-05-10 | Univ Oxford Innovation Ltd | System |
| KR20260005248A (ko) * | 2023-03-24 | 2026-01-09 | 주식회사 핀테라퓨틱스 | Gspt1 분해 화합물 및 분해 방법 |
| WO2025003466A1 (en) * | 2023-06-30 | 2025-01-02 | Universitaet Heidelberg | Peptides as antagonists of ikaros zinc finger family (ikzf) proteins to activate the immune system against tumor cells |
| KR20260035992A (ko) * | 2023-07-14 | 2026-03-13 | 글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. | 글루타르이미드 이소인돌리논 골격을 기반으로 한 화합물 |
| CN122249432A (zh) * | 2023-11-21 | 2026-06-19 | 普泰尔生物科技株式会社 | 新型化合物及其用途 |
| JP7901265B2 (ja) | 2024-03-22 | 2026-08-05 | ブリストル-マイヤーズ スクイブ カンパニー | 新規fak分解化合物およびその使用 |
| CN119708220B (zh) * | 2024-12-23 | 2025-08-05 | 无锡傲锐东源生物科技有限公司 | 抗人yap1蛋白单克隆抗体及其杂交瘤细胞株和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994A (en) | 1849-01-02 | Combined beading-tool and circular shears | ||
| US136A (en) | 1837-03-03 | Mode of molding candles | ||
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE368122T1 (de) | 1999-04-29 | 2007-08-15 | Cell Genesys Inc | Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer |
| CN1352301A (zh) * | 2000-11-02 | 2002-06-05 | 上海博德基因开发有限公司 | 一种新的多肽——人二氢乳清酸酶9.46和编码这种多肽的多核苷酸 |
| GB201710620D0 (en) * | 2017-07-03 | 2017-08-16 | Glaxosmithkline Intellectual Property Ltd | Targeted protein degradation |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| SG11202003415XA (en) * | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019089592A1 (en) * | 2017-10-31 | 2019-05-09 | The General Hospital Corporation | Molecular switch-mediated control of engineered cells |
| WO2020219742A1 (en) * | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN110438112B (zh) * | 2019-08-16 | 2021-09-10 | 苏州科宁多元醇有限公司 | 一种d-阿洛酮糖-3-差向异构酶的突变体及其应用 |
-
2022
- 2022-08-05 JP JP2024506674A patent/JP2024528988A/ja active Pending
- 2022-08-05 CA CA3223636A patent/CA3223636A1/en active Pending
- 2022-08-05 TW TW111129489A patent/TW202321278A/zh unknown
- 2022-08-05 PE PE2024000202A patent/PE20252433A1/es unknown
- 2022-08-05 CN CN202280054544.9A patent/CN117794554A/zh active Pending
- 2022-08-05 AR ARP220102109A patent/AR126718A1/es unknown
- 2022-08-05 WO PCT/US2022/074589 patent/WO2023015283A1/en not_active Ceased
- 2022-08-05 EP EP22790152.7A patent/EP4380582A1/en active Pending
- 2022-08-05 US US17/817,777 patent/US20230095912A1/en active Pending
- 2022-08-05 IL IL309653A patent/IL309653A/en unknown
- 2022-08-05 MX MX2024000901A patent/MX2024000901A/es unknown
- 2022-08-05 AU AU2022324621A patent/AU2022324621A1/en active Pending
- 2022-08-05 KR KR1020247007065A patent/KR20240043780A/ko active Pending
-
2024
- 2024-01-31 CL CL2024000305A patent/CL2024000305A1/es unknown
- 2024-02-01 CO CONC2024/0001133A patent/CO2024001133A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202321278A (zh) | 2023-06-01 |
| CA3223636A1 (en) | 2023-02-09 |
| EP4380582A1 (en) | 2024-06-12 |
| CL2024000305A1 (es) | 2024-06-14 |
| JP2024528988A (ja) | 2024-08-01 |
| IL309653A (en) | 2024-02-01 |
| CO2024001133A2 (es) | 2024-03-07 |
| MX2024000901A (es) | 2024-02-06 |
| AU2022324621A1 (en) | 2024-01-18 |
| US20230095912A1 (en) | 2023-03-30 |
| AR126718A1 (es) | 2023-11-08 |
| CN117794554A (zh) | 2024-03-29 |
| KR20240043780A (ko) | 2024-04-03 |
| WO2023015283A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125212T1 (el) | Συνθεσεις τροποποιημενου mrna | |
| PE20211696A1 (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor | |
| CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
| CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
| CO2022009248A2 (es) | Anticuerpos anti-cd73 y usos de estos | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| CL2017002345A1 (es) | Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr | |
| CL2018000543A1 (es) | Ensamble de polipéptido quimérico y métodos para hacer y usar el mismo | |
| ECSP19011185A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 | |
| ECSP10010191A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| PE20190436A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| MX2021000328A (es) | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. | |
| PE20181026A1 (es) | Metodos y composiciones para tolerancia a los herbicidas en plantas | |
| MX2018015414A (es) | Terapia de célula t adoptiva mejorada. | |
| PE20191703A1 (es) | Formatos mejorados de receptor de union a antigeno | |
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| PE20241994A1 (es) | Proteina mutante de interleucina-2 y fusion de la misma | |
| ZA202000961B (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods | |
| CL2008002860A1 (es) | Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido. | |
| MX2009013765A (es) | Polipeptidos y polinucleotidos para artemina y ligandos relacionados, y metodos de uso de los mismos. | |
| BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
| MX2015000397A (es) | Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos. |